Live Breaking News & Updates on பாலாஜி பிரசாத்|Page 6

Stay updated with breaking news from பாலாஜி பிரசாத். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ELANCO ANIMAL HEALTH INC (ELAN) Q4 2020 Earnings Call Transcript


ELANCO ANIMAL HEALTH INC (ELAN) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
ELANCO ANIMAL HEALTH INC (NYSE: ELAN)
Popular Searches
Operator
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Elanco Animal Health Q4 2020 Earnings Conference Call. [Operator Instruction] Following the presentation, we will conduct a question-and-answer session, open to analysts only. [Operator Instructions] Before turning the meeting over to management, please be advised that this conference call will contain statements that are forward-looking and subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. I would like to remind everyone that this conference call is being recorded February 24, 2021. ....

United States , David Risinger , Melina Santoro , Raymond James , Erin Wright , Goldman Sachs , Katy Grissom , Balaji Prasad Barclays , Tiffany Kanaga , Melina Santoro Morgan Stanley , David Westenberg , Michael Ryskin , Todd Young , Elliot Wilbur Raymond James , Jeff Simmons , Navin Jacob , Elliot Wilbur , Morgan Stanley , Elanco Animal Health Inc , Elanco Animal Health , Credit Suisse , Kathy Miner Cowen Company Analyst , Bayer Animal Health , Motley Fool , Cowen Company , Exchange Commission ,

Phibro Animal Health Corp (PAHC) Q2 2021 Earnings Call Transcript


Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Phibro Animal Health Corporation Q2 2021 Conference Call. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Damian Finio, Chief Financial Officer. Thank you. Please go ahead.
Damian Finio
Chief Financial Officer
Thank you, Mariama. Good morning, and welcome to the Phibro Animal Health earnings call for our second quarter ended December 31, 2020. I am Damian Finio, Chief Financial Officer of Phibro, and I m joined on today s call by Jack Bendheim, Phibro s Chairman, President and Chief Executive Officer. We will cover key themes for the quarter, our second quarter financial results, guidance for third quarter ending March 31, 2021, and then open the line to respond to your questions. ....

United States , South Africa , Michael Ryskin , David Risinger , America Merrill Lynch , Jack Bendheim , Melina Santoro , Erin Wright , Haley Christofides , Kevin Kedra , David Westenberg Guggenheim , Melina Santoro Morgan Stanley , David Westenberg , Balaji Prasad , Jackc Bendheim , Damian Finio , Phibro Animal Health , Balaji Prasad Barclays Bank Analyst , Virtual Animal Health Summit , Phibro Animal Health Corporation , Credit Suisse , Kevin Kedrag Research Analyst , Dg Research , Animal Health , Phibro Animal Health Corp , Michael Ryskin Bank ,

Ligand Pharmaceuticals Inc (LGND) Q4 2020 Earnings Call Transcript


Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Ligand Pharmaceuticals Q4 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Patrick O Brien. Thank you. Please go ahead.
Patrick O Brien
Investor Relations
Thank you, Brandy. And welcome to Ligand s fourth quarter of 2020 financial results and business update conference call. All of our speakers for today s call are in separate locations. Speaking today for Ligand will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO. We will use non-GAAP financial measures and some of our statements will be forward-looking. Additional information concerning risk factors and other matters concerning Ligand can be found in our Ligand s earning press release and our periodic filings with the SEC. Ligand undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this confe ....

United States , Matt Hewitt , Patrick Obrien , Matt Foehr , Matthew Foehr , Matt Korenberg , Balaji Prasad Barclays , John Higgins , Joe Pantginis , Balaji Prasad , Scott Henry , Dana Flanders , Matt Hewitt Craig Hallum Capital Group Analyst , Ligand Pharmaceuticals , Ligand Pharmaceuticals Inc , Jazz Pharmaceuticals , Cystic Fibrosis Foundation , Dana Flanders Guggenheim Securities , Stanford University , Joseph Pantginis Hc Wainwright Co , Vice President , Chief Financial , Analyst Day , Chief Operating , Antibody Discovery Tech , Biological Intelligence ,